dc.contributor.author | Jiang, Mo | |
dc.contributor.author | Braatz, Richard D. | |
dc.date.accessioned | 2019-07-09T19:54:40Z | |
dc.date.available | 2019-07-09T19:54:40Z | |
dc.date.issued | 2019-04-29 | |
dc.date.submitted | 2018-01-08 | |
dc.identifier.issn | 1466-8033 | |
dc.identifier.uri | https://hdl.handle.net/1721.1/121555 | |
dc.description.abstract | Crystallization is an effective, low-cost purification & formulation process widely applied to pharmaceuticals
and fine chemicals. This review describes recent advances in research on lab-scale solution-based continuous crystallization, including (1) a 5-step general design procedure; (2) key design/operational parameters;
(3) process intensification strategies; and (4) a case study. The continuous crystallizers reviewed include
mixed-suspension mixed-product removal, fluidized beds, oscillatory baffled flow, and tubular laminar/segmented/slug-flow crystallizers. Their corresponding design and operational considerations are summarized in terms of general parameters (e.g., residence time), and crystallizer-specific parameters and strategies (e.g., mixing strategies). In-line nucleation and crystal modification methods are categorized, including use
of micromixers, wet milling, ultrasonication, temperature cycling, and recycling selection (filtration, sedimentation). Throughout the article, links are drawn with extensive existing knowledge of batch crystallizers,
to facilitate the understanding and design of continuous crystallizers. | en_US |
dc.publisher | Royal Society of Chemistry (RSC) | en_US |
dc.relation.isversionof | 10.1039/c8ce00042e | en_US |
dc.rights | Creative Commons Attribution Noncommercial 3.0 unported license | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/3.0/ | en_US |
dc.source | Royal Society of Chemistry (RSC) | en_US |
dc.title | Designs of continuous-flow pharmaceutical crystallizers: developments and practice | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Jiang, Mo, and Richard D. Braatz. “Designs of Continuous-Flow Pharmaceutical Crystallizers: Developments and Practice.” CrystEngComm 21, no. 23 (2019): 3534–51. © 2019 The Royal Society of Chemistry | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Chemical Engineering | en_US |
dc.relation.journal | CrystEngComm | en_US |
dc.eprint.version | Final published version | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
dspace.date.submission | 2019-05-14T18:10:05Z | |